When is skin testing for vancomycin indicated and how should it be performed?

Vancomycin Skin Testing: Not Routinely Indicated or Validated

Vancomycin skin testing is not validated or standardized for clinical use, and there is no established role for routine skin testing in evaluating vancomycin hypersensitivity reactions. Unlike penicillin allergy evaluation where skin testing is well-established, vancomycin presents unique diagnostic challenges that make traditional skin testing unreliable.

Why Vancomycin Skin Testing Differs from Penicillin

The 2022 Drug Allergy Practice Parameter provides clear guidance on skin testing for beta-lactam antibiotics but notably does not include recommendations for vancomycin skin testing 1. This absence is deliberate—the immunochemistry and mechanisms of vancomycin reactions are fundamentally different from penicillins:

• Penicillin skin testing detects IgE-mediated reactions with >95% negative predictive value
• Vancomycin reactions are predominantly non-IgE-mediated, primarily through Mas-Related G Protein-Coupled Receptor-X2 (MRGPRX2) activation 2
• True IgE-mediated vancomycin allergy is rare and mechanistically unproven 2

The Problem with Traditional Vancomycin Skin Testing

Historical data demonstrates why vancomycin skin testing is problematic:

• All healthy volunteers tested positive to intradermal vancomycin at concentrations ≥10 μg/mL, showing dose-dependent flare responses 3
• Skin test results did not correlate with severity of "red man syndrome" (vancomycin infusion reaction) 3
• This universal positivity makes traditional skin testing non-discriminatory and clinically useless

Emerging Research: Dose-Response Intradermal Testing

Recent research suggests a modified approach may have utility, though this remains investigational and not ready for routine clinical use:

A 2024 study found that intradermal dose-response testing could potentially differentiate vancomycin infusion reaction (VIR) from tolerant patients 4:

• VIR patients had mean EC50 of 328 μg/mL versus 1166 μg/mL in tolerant subjects (p<0.0001)
• All VIR subjects reported local pruritus during testing versus 60% of tolerant subjects
• Basophil activation testing was insufficient (consistently <2% CD63+ basophils)

However, this methodology requires validation before clinical implementation and should only be performed in specialized allergy centers with appropriate expertise 5, 4.

Clinical Approach to Vancomycin Reactions

For Immediate Reactions (During or Shortly After Infusion):

Most are vancomycin infusion reactions (VIR), not true allergy:

• Symptoms: pruritus (82%), flushing (82%), hives (46%), angioedema (27%), dyspnea (19%) 4
• Mechanism: MRGPRX2-mediated mast cell degranulation, not IgE 2
• Management: slow infusion rate, supportive care, consider premedication with antihistamines
• These patients can typically be rechallenged with slower infusion rates

For Severe or Recurrent Immediate Reactions:

• Refer to allergy/immunology for evaluation of possible IgE-mediated mechanism 2
• Consider emerging dose-response intradermal testing protocols at specialized centers 4
• Do not use traditional skin testing—it will be positive in everyone

For Delayed Reactions:

• Spectrum ranges from benign morbilliform eruptions to severe cutaneous adverse reactions (SCAR) including DRESS 2
• No validated skin testing methods exist for delayed vancomycin reactions 2
• Patch testing may be considered per general drug allergy guidelines (30% in petrolatum/water, read at D2, D4, and 1 week) 6, but lacks validation for vancomycin specifically
• Severe reactions (DRESS, SJS/TEN) are absolute contraindications to rechallenge

Key Pitfalls to Avoid

1. Do not perform traditional prick or intradermal testing expecting to rule out vancomycin allergy—everyone will test positive at sufficient concentrations
2. Do not restrict vancomycin based solely on infusion reactions—most can be managed with rate adjustment
3. Do not confuse VIR with true allergy—this leads to unnecessary drug restriction and use of inferior alternatives
4. Do not attempt rechallenge in patients with DRESS or other severe cutaneous reactions

Bottom Line

Unlike penicillin allergy where skin testing is a validated diagnostic tool, vancomycin skin testing has no established clinical role. Most vancomycin "allergies" are actually infusion reactions manageable with rate adjustment. For patients requiring vancomycin who experienced reactions, focus on detailed history to distinguish VIR from true hypersensitivity, and refer complex cases to allergy specialists rather than attempting skin testing 2.